The urokinase-type plasminogen activator (UPA) is considered to play a key role in the process of invasion and metastasis. In several independent studies, in a variety of cancer types (e.g. of the breast, colon, stomach, lung, ovary), high antigen levels of UPA in tumour extracts have been associated with rapid disease progression. In these studies, different sets of antibodies and standards (often as commercially available uFA ELISA kits) have been used. The standards provided with the different UPA ELISA kits are different from each other in both composition and source. In addition, the different UPA ELISA kits use antibodies which differ in specificity and afBnity for the various forms of UPA including pro-UPA, HMW-uI?A, LMW-UPA, the aminoterminal fragment (ATF) and complexes with inhibitors (FAI-1 and PAI-2) and the receptor @FAR). Further, the composition of tumour tissue extraction buffers differ significantly among the published studies. Thus, it is not surprising that the ranges of cytosolic ul?A levels reported differ considerably even when measured within the same tumour type. These discrepancies led the EORTC Receptor and Biomarker Study Group, in conjunction with the BIOMED-1 consortium on 'Clinical Relevance of Proteases in Tumour Invasion and Metastasis', to organise a workshop to study the characteristics associated with six different UPA immunoassays (ELISA) used in clinical studies reported in the literature. Although the absolute UPA antigen values measured with the respective UPA ELISA kits differed, high correlations were obtained for any two of the four UPA ELISA kits finally applied to sets of breast cancer cytosol preparations. The preparations used at present as standards in the various UPA ELISA kits are not representative of actual human breast cancer cytosols. Thus absolute standardisation is only possible by using a common reference sample (breast cancer cytosol) and similarly composed ELISA uPA kits. Then it will be possible to generate comparable data on clinical tissue as well as to check for batch-to-batch variations within particular ELISA kits. Copyright 0 1996 Elsevier Science Ltd Key words: UPA, ELNSA, breast cancer, standardisation, quality assurance, EORTC EurJCuncer, Vol. 32A, No. 8, pp. 1371-1381,1996 INTRODUCTION disease. Lymph node status is recognised as one of the best IN BREAST cancer, the selection of high-risk patients has always clinical discriminants between good and bad prognosis. Yet been difficult due to the unpredictable biological course of the almost 30% in node-negative patients will relapse within a few months, while in node-positive patients approximately 25% are free of disease 10 years after primary surgery [ 11.
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tissue. Early work showed that oestrogen receptor positivity was associated with longer survival [24] , most probably because oestrogen receptor-positive patients are the ones most likely to respond to steroid hormone therapy. Quantification of oestrogen receptor is important because the chance of patients responding to hormonal therapy is proportional to the oestrogen receptor content in the primary tumour [5-71. For this reason, determination of biological indices should be quantitative, rather than qualitative. In consequence, quality assurance groups have been established to monitor tumour biology factors, e.g. steroid hormone receptors [8-lo] .
To increase the knowledge of the biological basis of tumour development, various studies have been undertaken to look into the mechanism of tumour invasion. A major component of tumour invasion is the action of tumour-associated proteases in disrupting the surrounding basement membrane and the adjacent stromal matrix. The action of these proteases is under control of a cascade response which induces activation of proteolytically active urokinase (UPA) from its precursor pro-uPA [ 1 l-131 . Recent studies have suggested that the uPA level might be a strong biological indicator of prognosis in breast cancer [14, 15] and of response to endocrine therapy in recurrent breast cancer [16] . There is also broad interest in the relationship of uPA levels with other types of cancer [17] [18] [19] . Various ELISAs for UPA have been established and reported in the literature, and some of these are commercially available.
During a workshop held in Nijmegen, The Netherlands, under the auspices of the EORTC and the BIOMED-1 programme supported by the European Community, a number of UPA ELISAs were tested. The present report contains results of uPA measurements obtained during this workshop supplemented with data collected in later studies. Attention was paid to the immunological potencies of various standards, to parallelism, to detection limits and to within-and betweenassay variations achievable.
It should be kept in mind that the purpose of this study was not to evaluate the quality of the individual methods, but to better understand the characteristics associated with each of the procedures.
PATIENTS AND METHODS orgunimion
Within the framework of both the Receptor and Biomarker Study Group of the EORTC and a consortium of the BIOMED-1 programme 'Clinical Relevance of Proteases in Tumour Invasion and Metastasis', a workshop was organised in Nijmegen. A number of different ELISA kits were used to assess UPA antigen in primary breast cancer. The companies that generously made their reagents available are American Diagnostica (Greenwich, U.S.A.), Biopool (Umea, Sweden), Oncogene Science (Cambridge, U.S.A.), Sangtec Medical (Bromma, Sweden) and Technoclone (Vienna, Austria). In addition, the group was provided with the relevant reagents to determine uPA by the Finsen Institute (Copenhagen, Denmark), a laboratory with a longstanding experience in the uPA field. Comparable reagents are commercially available from Monozyme (Denmark). Many, but not all, participants had previous experience with these assays. It is reasonable to assume that the experience of the operators will have positively influenced the performance of the assays during the workshop. At the workshop, measurements of PAI-1, a natural occurring inhibitor, and the receptor uPAR, were also investigated and will be the subject of future publications.
Samples
Primary breast cancer biopsies from our tumour bank (-80°C) were analysed. Xenografts, raised in nude mice after implanting MDA-NB-231 human breast cancer cells, were kindly provided by the Finsen Institute. Biopsies and xenografts were homogenised (microdismembrator) in EORTC buffer (20 mM KaHPO,/KH,PO,, 1.5 mM KaEDTA, 3 mM sodium azide, 10 mM monothioglycerol, 10% [v/v] glycerol/water, pH 7.4), centrifuged at 8OOg, the supernatant collected and subjected to cennifugation for 1 h at 1OOOOOg at 4°C. This procedure has for many years been used to make cytosols for measuring the oestradiol and progesterone receptor levels. It is worthwhile mentioning that this procedure was used to collect cytosolic proteins. However, UPA in addition to its free state is also bound to its receptor, uPAR. Therefore, in various published studies, detergent-containing buffers have been used for extraction of UPA. However, it has been the experience of various laboratories that while the uPA content of these extracts are much higher than the values obtained in the EORTC cytosol, there is a close correlation between the values obtained with the two techniques [20] (see also the Results section). Dilution of cytosols was performed applying dilution buffers recommended for that particular assay procedure. The following extraction buffers were used for pellet extraction: (1) Jiinicke buffer: 20 mM Tris-HCl, 125mM NaCl containing 1% Triton X-100, pH8.5 [2OJ; and (2) Camiolo buffer: 75 mM potassium acetate, 0.3 M NaCl, 0.1 M L-arginine, 10 mM KaEDTA, 0.25% Triton X-100, pH 4.2 [21] .
Standards
The NIBSC UPA standard 87J594, consisting of highly purified HMW uPA derived from human urine, was kindly provided by Dr P.J. Gaffiey (NIBSC, U.K.). Until now, this standard has not officially been assigned an antigen value. For internal purposes, NIBSC use the value of 32.5 &ampoule. This standard for high molecular weight urokinase (HMW-UPA) is alternatively named HMW-two chain UPA (HMWtc-uPA) .
The UPA standard provided with the American Diagnostica ELISA kit, designated as SC-UPA, is a glycosylated pro-uPA, secreted by a cell line and purified from conditioned culture media. The Grtinenthal standard (Saruplase@) is a recombinant non-glycosylated pro-urokinase produced by E. coli, generously provided by Griinenthal GmbH, Stolberg, Germany. The pro-uPA content has been determined by Gtinenthal on the basis of amino acid determination. The Finsen laboratory, in their published studies, used the NIBSC standard as well as the Grtinenthal preparation, calibrated against the former
WI.

Analytical methods
The basic characteristics of the different ELISAs are shown in Table 1 , including the type and range of standards used, the type of primary and secondary antibodies employed and information about the forms of UPA recognised by the relevant assay system. This information was provided by the manufacturers.
The ELISAs were all of the sandwich type. The ELISAs were all performed in precoated microtitre plates using spec- trophotometric determinations, whereas the LIA type of ELISA, using a luminometric detection system was performed in antibody precoated tubes. The ELISAs were used according to the instructions provided by the manufacturers. The ELISA developed in the Finsen laboratory was used as previously described [ 181. No major difficulties were noticed while performing the assqys.
The lower limit of detection was defined as three standard deviations in the measurement of zero analyte. The overall coefficient of variation (CV) was calculated using the formula overall CV% = square root of Z [CV%JZIn). Figure 1 shows representative standard curves obtained using six different UPA procedures and the standards provided by the companies with their different kits. All curves were more or less curvilinear. The Finsen and American Diagnostica procedures (Figure 1 a, b ) employ a working range from 0 to 1 ng/ml. The lower limits of detection were nearly identical. The overall CVs of the standard points were 8.1 and 7.5%, respectively. These characteristics are in agreement with the information given in the kit-insert.
RESULTS
Standard cupues in different assay procedures
The standard curve obtained using the Sangtec kit ( Figure  lc) shows the relationship between relative light units (RLUs) and the amount of UPA, up to 4 r&ml. The lower detection limit was calculated to be as low as 0.010 &ml (1.0 pg per tube), with an overall CV of 4.4%. The span of the standard curve in the Oncogene Science procedure ( Figure Id ) ranged from 0 to 0.35 ng/ml. In this very sensitive assay, the detection limit was 0.002 r&ml. In contrast to the aforementioned assays, the Biopool uPA assay (Figure le) was specifically designed for the quantitative determination of uPA in plasma samples. For this purpose, the detection limit of 0.277 ng/ml is adequate. The Technoclone assay (Figure lr> is also specifically intended for the determination of uPA in plasma, and the highest standard used is 10 r&ml. The lower limit of detection was calculated at 0.384 &ml, with an overall CV of 4.9%.
In the four most sensitive assays (Finsen, American Diagnostica, Sangtec, Oncogene Science) five different types of standards were tested. Figure 2 shows that the slopes of the curves in all methods varied considerably. Obviously, in all assay methods, the values measured in unknowns depend strongly on the standard applied. It is worth noting that the immunoreactive potencies, as reflected by the absorbance values, of the different standards do not follow the same order in the different assay procedures. For instance, in three out of the four procedures (Finsen, Sangtec, Oncogene Science) the HMW-uPA standard provided with the Sangtec kit, gave the highest signal, whereas the lowest signal was evoked by the Biopool pro-uPA standard. In contrast, in the American Diagnostica procedure little difference in optical density was observed using these two standards.
Correlation and comparison between cytosohc t&A assay methods Figure 3a shows uPA values measured in 117 breast cancer cytosols both with the American Diagnostica procedure and the Finsen assay method (both methods used in previous publications). The values obtained by the American Diagnostica kit ranged from 0 to 8.14 ng/ml; the values obtained by the Finsen procedure ranged t?om 0.16 to 9.05 r&ml. In the Finsen procedure the pro-uPA from Griinenthal was used as a standard and in the American Diagnostica assay the scuPA standard provided with the kit. Least squares regression analysis of the data gave the relationship y = 1.13x + 0.17. the uPA values measured with the American Diagnostica were used. The values obtained by the American Diagnostica procedure were lower than the detection limit, whereas in the procedure ranged between 0.82 and 8.58 &ml; in the SangFinsen procedure the values were low but measurable. These tee procedure the values were between 0.06 and 4.57 ng/ml. five samples were excluded from the Difference Plot. Of the These values were highly correlated (Figure 3b ). The relation American Diagnostica values 87 were lower, 1 was equal and between the Sangtec values and the American Diagnostica 29 were higher than in Finsen procedure.
values is defined by y = 0.60x -0.36. The respective DifferBreast cancer cytosols (n = 18) were also analysed with ence Plot is shown in Figure 4b . Although the number of both the Sangtec procedure and the American Diagnostica observations is rather small, there is a tendency for a decrease kit. In both assays the standards provided by the companies in percentage difference at higher uPA concentrations. A number of other breast cancer cytosols (n = 34) were analysed with both the Chicogene Science and the American Diagnostica kit. In this series the span of uPA values obtained with the latter ranged between 0.08 and 4.97 ng/ml and the Oncogene Science values ranged between 0.21 and 10.6ng/ml. Figure 3c shiows the linear relation with a high correlation coefficient. The relation between UPA values obtained with the Oncogene Science and the American Diagnostica kit is defined by y = 2.10x + 0.38. The Difference Plot is shown in Figure 4c , implying that over the whole range of UPA concentrations the difference between the results obtained with both procedures is remarkably constant.
The repeatability of the three assay procedures is reflected by the CVs shown in Tablle 2. The UPA values measured were, for each procedure, divided into four quartiles. The CVs calculated from duplicates were averaged and are shown in the last column of the table. All coefficients of variation calculated were acceptable. The CV calculated from the 18 duplicate Sangtec measurements was 14.6%. The kits from Biopool and Technoclone, designed for UPA measurement in plasma, were not included in these experiments because they would require undiluted cytosol samples.
Dilution of cytosolic samples
The different assay procedures recommend that samples be diluted to within a specified range of protein content prior to assay. Values corrected for dilution should give the same result irrespective of the extent of dilution. Dilution experiments were carried out using both the Finsen assay and the American Diagnostica procedure. Such experiments are often referred to as parallelism studies because dilutions of sample should parallel the standard curve. In Table 3 the results obtained with the Finsen procedure are displayed. A human breast cancer cytosol (no. l), prepared according to the EORTC guideline, was diluted with the appropriate dilution buffer obtaining dilutions from l/4 to l/64. The actual UPA concentrations measured in the diluted samples ranged from 0.067 to 0.866 @ml. The corresponding CVs calculated from the duplicates ranged from 0.9 to 6.3%. Multiplying these concentrations by the appropriate dilution factor will give the actual UPA value in the undiluted sample. The mean of these UPA values was 3.7 rig/ml and the CV was calculated to be 9.4%. Evidently, no systematic error could be detected, i.e. a perfect parallelism was observed. Three different 'xenograft cytosols' (nos 2, 3 and 4) with high UPA concentrations were diluted even further, obtaining dilutions down to 11400. The CVs observed analysing UPA in the dilutions were <5%. Again, no systematic error was observed and parallelism was ascertained. In another set of dilution experiments performed with the American Diagnostica procedure, comparable results were obtained (see Table 4 ). No systematic decrease or increase of uPA levels was seen upon dilution. 
&A in tissue pellet extracts
In the experiments described so far, UPA was assessed in cytosolic extracts employing the routine EORTC buffer as originally described for determination of steroid hormone receptors. However, UPA was also measured in tumour pellet extracts. Ten mammary tumours were homogenised in the EORTC buffer and the homogenates were pooled and divided into two equal parts. After centrifugation at IOOOOOg the cytosol was separated from the pellets. One pellet was extracted with a buffer previously described by J%nicke and colleagues [20] which contains the non-ionic detergent Triton X-100 (pH 8.5). The other pellet was extracted with a buffer described by Camiolo and coworkers [21] . This latter buffer has a high ionic strength and a low pH (pH 4.2). Both extracts were diluted to various extents not with the extraction buffers but with the appropriate dilution buffers belonging to the particular assay procedure. uPA was measured with six different assay procedures.
The various dilutions in which uPA was assayed are shown in Table 5 . The table shows that for the various assay procedures the dilutions varied, taking into account the different sensitivities of the asssay procedures. With each assay procedure, five different dilutions of both the Camiolo and Janicke extracts were analysed and each was measured five times. The results are presented in Table 6 . It is noteworthy that the uPA values in the JsLnicke extracts were lower than the levels present in the Camiolo extracts. This holds for all six assay procedures. Obviously, because of the use of different internal standards and different antibodies, a large variation was observed between the uPA values obtained employing the different assay procedures.
The degree of parallelism, which can be deduced from the uPA values measured in the different dilutions, was higher when the pellet extraction was performed with the J&nicke buffer. This holds for three of the assay procedures (Finsen, American Diagnostica and Sangtec). The strongest parallelism was observed using the Oncogene Science kit. In those assay procedures which were developed for uPA analysis in plasma samples, less diluted tumour extracts could be used. In those cases, matrix effects resulted in non-parallelism.
UPA values in cytosolfiactions versus corresponding pellet extracts
Nine primary breast cancers were homogenised in EORTC bufler and uPA was measured in the cytosols. The 1OOOOOg pellets were extracted with the Camiolo buffer and uPA was measured in these extracts ( Figure 5 ). There was a strong The UPA values presented in the figure are expressed per mg protein present in the samples. When the UPA concentrations were expressed per ml of sample, the Camiolo extracts contained 10 times higher UPA values than the corresponding cytosols 0, = 10.48x -5.57, r = 0.924).
Analysis of a lyophilised quality control sample
To be able to perform a.dequate internal and external quality control on the assays, a representative and stable control sample is needed. Therefore, cytosols prepared from primary breast cancer tissues were pooled and the pool was spiked with recombinant pro-uPA and lyophilised. This control sample was analysed on 26 separate days divided over a period of 18 months (Figure 6 ). Three operators performed the assays using various batches of the UPA kit from American Diagnostica. The mean of 26 uPA concentrations was 10.9 r&ml with an overall CV of 11.5%. No statistically significant trend was observed.
DISCUSSION
The proteolytic enzyme UPA, which activates plasminogen to the protease plasmin, plays an important role in cancer invasion and metastasis.
In a preliminary report, in. 1988, evidence was presented that high UPA enzyme activity in breast carcinoma extracts correlated with a shortened diseasefree interval for the patients [ 141. Two years later, in 1990, two groups of investigators, Jlnicke and coworkers and D&l+ and coworkers independently reported measurements of ul?A antigen content in breast cancer tissues [15, 241. Applying completely different UPA ELISAs, these authors reported that a high level of immunoreactive uPA is significantly correlated with high relapse rate and associated with poor prognosis. These observations were later extended and confirmed in other studies [25-271. The uPA ELISA kits employed differed in the type of antibodies used, in the type of standards and in the instructions on how the tissue extracts had to be prepared. Notwithstanding these differences in analytical features, causing different ranges of values and cut-off points, the same clinical relevance for UPA was observed in all these studies.
The different sandwich-type uPA ELISAs used in those particular studies were included in the experiments of the present study, along with reagent kits marketed more recently or designed for UPA measurement in plasma. It was found *Mammary tumour cytosol. tColon carcinoma cytosol. SMammaty tumour cytosol spiked with 8.4 ng/ml pro-uPA.
that those kits developed for the analysis of tumour cytosols, When, during our workshop, sets of breast cancer cytosol all reached sensitivities of less than 32 pg uPA per ml, which preparations were analysed applying different UPA ELISAs, is satisfactory. The two UPA ELISAs, initially developed for different absolute uPA values were observed, although high measuring UPA in plasma, did not reach the desired sensicorrelations (Pearson) were obtained for any two of the four tivity, but recently these assays have been redesigned and are UPA ELISAs applied. It is acknowledged that, strictly speaknow available for tumour extract analysis. The within-assay ing, the Pearson correlation coefficient is a poor index of the CVs observed, employing the various assay methods, were degree of agreement between two methods [23] . How closely acceptable, and all kits designed for tumour analysis displayed two methods agree is a question which is more accurately an acceptable to excellent degree of parallelism.
answered by employing a calculation of the differences Cytosol; uPA (&ml) Months of storage between measurements. Scatter plots of the per cent differences versus the mean of the two methods provide a clear visual indication of the outliers which occur especially at low concentrations.
It is important to note that the uPA values measured with the various uPA ELISAs will depend on the efficiency with which the different sets of UPA antibodies employed detect the various forms of uPA present in the tissue cytosol. Indeed, uPA can occur in viva in different molecular forms: as a single chain pro-enzyme (pro-uPA); as a high molecular weight two chain molecule HMW-UPA; and as a low molecular weight LMW-UPA. Besides these different forms, complexes of prouPA and HMW-uPA with the receptor for uPA,uPAR, are present. In addition, HMW-uPA, its receptor-bound form, and LMW-uPA can be complexed with the inhibitors PAIor PAI-2, complexes in which uPA-epitopes may be hidden, due to steric hindrance. Taken together, this implies that, in cytosols, uPA may be present as a mixture of various molecular forms and weights with different structures.
According to Biiessecker and colleagues [28] , polyclonal antibodies to uPA react with the distinct molecular forms of uPA to a similar degree when tested by ELISA. In contrast, monoclonal antibodies, due to their high epitope-specific recognition, may not a primi allow detection of distinct UPA forms and complexes. All the uPA ELISAs tested in the present study use monoclonal antibodies, and the information given by the manufacturers with the kit claim that most, if not all, of the uPA forms are recognised. However, no detailed studies regarding this aspect are available and therefore it has to be emphasised that the efficiencies with which the various forms are detected are reportedly unknown and remain to be determined.
The relative level of each molecular form of uPA present in cytosol may vary between different cytosols. The results of the present study suggest that this variation will be even greater when different ways of extraction are employed, e.g. including or excluding non-ionic detergents in the extraction buffer. Our results confirm earlier findings [25] which indicated that the uPA content in tumour tissue extracts, obtained by treating fresh tumour tissues with a Triton X-100 containing buffer, is much higher than the uPA level in extracts prepared by using the detergent-free EORTC buffer.
As far as the standards provided with the different kits are concerned, these are different in structure (e.g. glycosylated versus non-glycosylated) and in source (e.g. recombinant versus cell-culture supematants). The results obtained during the workshop disclosed large differences in immunological potencies of the different standard preparations, when they were tested in the various kits. The discrepancies observed cannot solely be ascribed to differences in calibration of the standards because the immunoreactive potencies, as reflected by the different absorbance values generated by different standards, do not follow the same order in the different uPA ELISAs. For example, when a particular standard in one of the uPA ELISAs evoked the highest absorbance value compared with other standards, the same standard evoked only an intermediate signal in another uPA ELISA. It is plausible to assume that the differential specificity of the different sets of antibodies is involved in causing these discrepancies. For proper evaluation of the UPA content determined in tumour cytosols, applying different uPA ELISAs, it should be kept in mind that these kits contain standards which may differ in composition, use antibodies which often differ in specificity but quantify an analyte which is heterogeneous in nature. Thus, it is hardly surprising that the ranges in uPA levels, measured with different ELISAs, vary considerably. However, it is not possible retrospectively to relate the absolute UPA values reported in the literature with those obtained with different ELISAs.
Taken together, this implies that multicentre studies with the goal of measuring uPA antigen in biological material in different laboratories should only be performed if the same type of uPA ELISA is used by all participating laboratories. In that case, the use of a stable reference material (tumour tissue extract) is very useful for normalisation of absolute values. In addition, such normalisation of values should result in lower interlaboratory CVs, but this will occur only if the intralaboratory variation of the determination of uPA by ELISA is acceptably low. If such a reference sample is used throughout the study and the values reported assessed centrally, not only changes within any laboratory but also any changes between two batches of uPA ELISA will be quickly detected. Therefore, it is strongly recommended that a reference tumour tissue extract sample is applied in order to assure a high standard of quality control. From the present study, it appears that lyophilised breast cancer cytosols are stable over a long period of time and can thus serve as an ideal reference sample for the assessment of uPA antigen in breast cancer tissue extracts.
